Altimmune (ALT) Cash from Operations (2010 - 2026)
Altimmune (ALT) posted quarterly Cash from Operations of 20942000.0 for Q1 2026, down 24.36% year-over-year from 27685922.44 in Q1 2025, and down 7.68% quarter-over-quarter from 19448000.0 in Q4 2025.
Altimmune (ALT) Cash from Operations (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Cash from Operations for 17 consecutive years, with 20942000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 24.36% year-over-year to 20942000.0; the TTM figure through Mar 2026 stood at 71637000.0 (up 10.82% YoY), while the FY2025 annual figure was 67535000.0, up 15.42% from the prior year.
- Cash from Operations slipped to 20942000.0 in Q1 2026 per ALT's latest filing, from 19448000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 11897000.0 in Q3 2025 and bottomed at 27118000.0 in Q3 2024.
- Historically, Cash from Operations has averaged 18042411.76 across 5 years, with a median of 18108000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 43.48% — and 2025, when it soared 56.13%.
- Altimmune's Cash from Operations stood at 17306000.0 in 2022, then advanced by 4.47% to 16533000.0 in 2023, then decreased by 10.48% to 18265000.0 in 2024, then decreased by 6.48% to 19448000.0 in 2025, then fell by 7.68% to 20942000.0 in 2026.
- Business Quant data shows ALT's Cash from Operations at 20942000.0 in Q1 2026, 19448000.0 in Q4 2025, and 11897000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -24.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.22 Mn |
| Jun 30, 2026 | -24.22 Mn |
| Mar 31, 2026 | -20.94 Mn |
| Mar 31, 2026 | -20.94 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Dec 31, 2025 | -19.45 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Sep 30, 2025 | -11.90 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Jun 30, 2025 | -19.35 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Mar 31, 2025 | -16.84 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Sep 30, 2024 | -27.12 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -18.11 Mn |
| Mar 31, 2024 | -16.36 Mn |
| Mar 31, 2024 | -16.36 Mn |